7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance

Pharmacokinetics describes what the body does to a drug, dictating the time course of its absorption, distribution, metabolism, and elimination. In anaesthetic practice, where intravenous hypnotics, analgesics, and muscle relaxants are titrated rapidly to profound clinical endpoints, a mathematical understanding of multi-compartment behavior, clearance kinetics, and infusion dynamics is indispensable.

---

1. Multicompartmental Pharmacokinetic Models and Rate Constants

Classic pharmacokinetic models simplify physiological tissues into distinct theoretical compartments based on perfusion and drug uptake characteristics. While single-compartment models assume instantaneous uniform mixing throughout the body, most anaesthetic agents exhibit multi-compartmental disposition best represented by two- or three-compartment mammillary models.

                     +-------------------------------+
                     | Shallow Peripheral (V2)       |
                     | Muscle, skin, viscera         |
                     +-------------------------------+
                               ^          |
                          k12  |          | k21
                               |          v
+-------------+      +-------------------------------+
|  IV Bolus / | ---> | Central Compartment (V1)      | ---> k10 (Elimination)
|  Infusion   |      | Vessel-rich group: brain,     |
+-------------+      | heart, liver, kidneys, lungs  |
                     +-------------------------------+
                               ^          |
                          k31  |          | k13
                               |          v
                     +-------------------------------+
                     | Deep Peripheral (V3)          |
                     | Adipose tissue, bone, poorly  |
                     | perfused connective tissues   |
                     +-------------------------------+

Compartment Characteristics and Perfusion Groups

• Central Compartment ($V_1$): Comprises the blood volume and the Vessel-Rich Group (VRG): brain, heart, liver, kidneys, and lungs. Although the VRG constitutes only ~10% of total body mass, it receives approximately 75% of resting cardiac output. Consequently, intravenous drugs rapidly equilibrate with $V_1$, yielding the initial peak plasma concentration ($C_0$).
• Rapid/Shallow Peripheral Compartment ($V_2$): Comprises the Muscle Group: skeletal muscle, skin, and splanchnic viscera. This group represents ~50% of body mass and receives ~19% of cardiac output. It acts as an intermediate reservoir during the early redistribution phase.
• Slow/Deep Peripheral Compartment ($V_3$): Comprises the Fat Group and Vessel-Poor Group (VPG): adipose tissue, bone, cartilage, and tendons. These tissues account for ~20-40% of body mass but receive only ~6% of cardiac output. Highly lipophilic anaesthetics accumulate extensively in $V_3$ during prolonged infusions.

Microscopic Rate Constants and Differential Equations

Transfer between compartments is described by first-order microscopic rate constants ($k_{ij}$), representing the fractional transfer of drug from compartment $i$ to compartment $j$ per unit time (expressed in $\text{min}^{-1}$):

• $k_{12}$: rate constant of drug movement from central ($V_1$) to shallow peripheral ($V_2$)
• $k_{21}$: rate constant of drug movement from shallow peripheral ($V_2$) back to central ($V_1$)
• $k_{13}$: rate constant of drug movement from central ($V_1$) to deep peripheral ($V_3$)
• $k_{31}$: rate constant of drug movement from deep peripheral ($V_3$) back to central ($V_1$)
• $k_{10}$: rate constant of irreversible systemic elimination directly from the central compartment ($V_1$)

The differential equations defining drug mass ($x_1, x_2, x_3$) over time are: $\frac{dx_1}{dt} = -(k_{10} + k_{12} + k_{13})x_1 + k_{21}x_2 + k_{31}x_3 + \text{Input}(t)$ $\frac{dx_2}{dt} = k_{12}x_1 - k_{21}x_2$ $\frac{dx_3}{dt} = k_{13}x_1 - k_{31}x_3$

Following an intravenous bolus injection, plasma concentration demonstrates a tri-exponential decline characterized by three distinct mathematical phases: $C_p(t) = A e^{-\alpha t} + B e^{-\beta t} + C e^{-\gamma t}$

1. $\alpha$-Phase (Rapid Distribution): Dominated by rapid mixing within $V_1$ and net transfer into shallow peripheral tissues ($V_2$). This accounts for the rapid termination of clinical effect after a single induction bolus of propofol or thiopental.
2. $\beta$-Phase (Slow Distribution / Redistribution): Reflects continued redistribution into deep tissues ($V_3$) alongside concurrent metabolic clearance.
3. $\gamma$-Phase (Terminal Elimination): Represents the return of drug from poorly perfused peripheral compartments back to $V_1$, where it is cleared by elimination organs. The slope is governed by the terminal elimination rate constant (often denoted $\beta$ in two-compartment and $\gamma$ in three-compartment systems).

---

2. Volumes of Distribution: Physiological Determinants and Steady State

The volume of distribution ($V_d$) is a theoretical, apparent parameter that relates the total mass of drug in the body ($A_{\text{body}}$) to its concentration in plasma ($C_p$): $V_d = \frac{A_{\text{body}}}{C_p}$

$V_d$ does not correspond to an actual anatomical fluid space; rather, it reflects the extent of tissue uptake relative to vascular retention.

Mathematical Subtypes of Distribution Volume

• Initial Volume of Distribution ($V_1$ or $V_{\text{initial}}$): The apparent volume immediately after intravenous administration before distribution occurs: $V_1 = \frac{\text{Dose}}{C_0}$. For propofol, $V_1$ is typically 15-30 L (~0.2-0.4 L/kg).
• Steady-State Volume of Distribution ($V_{d,\text{ss}}$): The sum of the apparent volumes of all compartments when drug concentrations in all tissues are in thermodynamic equilibrium with plasma: $V_{d,\text{ss}} = V_1 + V_2 + V_3$. It is independent of elimination rate and best reflects total body storage capacity at steady state.
• Volume of Distribution during Elimination Phase ($V_{d,\beta}$ or $V_{d,\text{area}}$): Calculated from systemic clearance and the terminal elimination rate constant: $V_{d,\beta} = \frac{CL}{\beta}$. Because active elimination occurs continuously during the distribution phase, $V_{d,\beta}$ is always larger than $V_{d,\text{ss}}$.

Clinical Trap: Acidic anaesthetic drugs (propofol, thiopental, etomidate, NSAIDs) bind primarily to albumin, whereas basic drugs (lidocaine, bupivacaine, alfentanil, sufentanil) bind predominantly to $\alpha_1$-acid glycoprotein (AAG). In severe malnutrition, hepatic cirrhosis, nephrotic syndrome, or critical illness, serum albumin drops precipitously. This increases the unbound, pharmacologically active free fraction ($f_u$) of acidic drugs, predisposing patients to exaggerated clinical effects and toxicity unless bolus doses are reduced.

---

3. Clearance Mechanics: Systemic, Hepatic, and Renal Elimination

Clearance ($CL$) is the volume of blood or plasma completely cleared of drug per unit time (expressed in $\text{mL/min}$ or $\text{L/h}$). Systemic clearance is additive across clearing organs: $CL_{\text{systemic}} = CL_{\text{hepatic}} + CL_{\text{renal}} + CL_{\text{pulmonary}} + CL_{\text{other}}$

Clearance relates the rate of drug elimination directly to plasma concentration, and can be derived from the area under the plasma concentration-time curve (AUC): $CL = \frac{\text{Rate of Elimination}}{C_p} = k_{10} \times V_1 = \frac{\text{Dose}}{\text{AUC}}$

Hepatic Clearance and Extraction Ratio

Hepatic clearance ($CL_H$) depends on total hepatic blood flow ($Q_H \approx 1.5\text{ L/min}$, ~25% of cardiac output) and the hepatic extraction ratio ($E_H$): $CL_H = Q_H \times E_H = Q_H \times \left(\frac{C_{\text{in}} - C_{\text{out}}}{C_{\text{in}}}\right)$ where $C_{\text{in}}$ and $C_{\text{out}}$ represent drug concentrations entering (portal vein and hepatic artery) and leaving (hepatic vein) the liver.

High Extraction Drugs (EH > 0.7)        Low Extraction Drugs (EH < 0.3)
- Clearance = Perfusion-limited         - Clearance = Capacity-limited
- CL_H ~ Q_H                             - CL_H ~ f_u x CL_intrinsic
- Sensitive to changes in blood flow     - Sensitive to enzyme induction/inhibition
- Examples: Propofol, Fentanyl,          - Examples: Thiopental, Diazepam,
  Etomidate, Ketamine, Lidocaine           Rocuronium, Phenytoin

1. High Extraction Ratio Drugs ($E_H > 0.7$): The liver has massive enzymatic reserve; clearance is rate-limited strictly by hepatic blood flow (flow-dependent clearance). Decreases in cardiac output, hypovolemia, $\beta$-blockade, or portosystemic shunting substantially decrease drug clearance. Conversely, competitive enzyme inhibition has little impact.
2. Low Extraction Ratio Drugs ($E_H < 0.3$): The liver clears only a small fraction of drug per pass; clearance is rate-limited by intrinsic metabolic enzyme activity ($CL_{\text{int}}$) and unbound fraction ($f_u$) (capacity-limited clearance). Changes in hepatic blood flow have minimal impact, whereas enzyme induction (rifampin, carbamazepine) or enzyme inhibition (cimetidine, ketoconazole) dramatically alters systemic clearance.

Renal Clearance

Renal clearance ($CL_R$) represents the net outcome of three distinct processes: $CL_R = (\text{Filtration} + \text{Secretion}) - \text{Reabsorption}$

• Glomerular Filtration: Clears free, unbound drug ($GFR \times f_u$). Protein-bound fractions cannot cross the glomerular capillary fenestrations.
• Active Tubular Secretion: Occurs in the proximal tubule via organic anion transporters (OATs) and organic cation transporters (OCTs). Carrier-mediated transport can clear both free and weakly protein-bound drug.
• Passive Tubular Reabsorption: Occurs in distal tubules. Lipophilic, un-ionized molecules diffuse passively down concentration gradients back into peritubular capillaries. Renal excretion of weak acids (e.g., phenobarbital, salicylates) is markedly accelerated by urine alkalinization (administering $\text{NaHCO}_3$ to raise urine pH above the drug's pKa, trapping the ionized species in the tubular lumen).

---

4. Elimination Kinetics: First-Order vs Zero-Order Dynamics

The fundamental distinction between first-order and zero-order kinetics is governed by the saturation status of metabolic enzymes and transport systems, mathematically defined by the Michaelis-Menten equation: $\text{Rate of Elimination} = -\frac{dC}{dt} = \frac{V_{\max} \times C}{K_m + C}$ where $V_{\max}$ is the maximal velocity of enzymatic elimination and $K_m$ is the Michaelis constant (substrate concentration at which the reaction velocity is half $V_{\max}$).

Clinical Pearl: Thiopental obeys linear, first-order kinetics at standard single induction doses (3-5 mg/kg) because plasma concentrations remain below metabolic saturation. However, during continuous infusions for refractory status epilepticus or intracranial hypertension, metabolic capacity of hepatic CYP enzymes becomes completely overwhelmed. Thiopental shifts to zero-order elimination, its clearance collapses, and its context-sensitive half-time extends to several days, predisposing patients to prolonged coma.

---

5. Context-Sensitive Half-Time (CSHT) and Redistribution Dynamics

The elimination half-life ($t_{1/2\beta}$) represents the time required for plasma concentration to drop by 50% during the terminal elimination phase, once complete equilibrium throughout all body compartments has been achieved. Because anaesthetic infusions are stopped long before full steady-state equilibrium with deep adipose reservoirs occurs, $t_{1/2\beta}$ notoriously fails to predict the recovery profile.

Definition of Context-Sensitive Half-Time

Context-Sensitive Half-Time (CSHT) is defined as the time required for the central plasma drug concentration to decrease by 50% following termination of a continuous intravenous infusion of a specified duration (the "context").

CSHT (min)
 ^
300|                                             ... Fentanyl
250|                                       ....''
200|                                 ...-''
150|                          ....--'
100|                   ....--'
 50|  -------------..--------------------------- Sufentanil / Alfentanil
 25|  ------------------------------------------ Propofol
  4|  ========================================== Remifentanil (~3-4 min invariant)
  0+-------------------------------------------->
   0     1     2     3     4     5     6     7     8   Infusion Duration (Hours)

Pharmacokinetic Mechanisms Across Key Intravenous Agents

• Remifentanil: Possesses an ester linkage that is rapidly cleaved by non-specific blood and tissue esterases. Its metabolic clearance is exceptionally high (~40 mL/kg/min), far exceeding hepatic blood flow. Because termination of effect is governed by relentless enzymatic destruction rather than redistribution, remifentanil's CSHT is invariant at ~3 to 4 minutes, regardless of whether the infusion runs for 15 minutes or 12 hours.
• Propofol: Exhibits high metabolic clearance ($CL \approx 20-30\text{ mL/kg/min}$) combined with rapid transfer into peripheral tissues. For infusions lasting under 2-3 hours, redistribution into $V_2$ and $V_3$ keeps CSHT low (~10-15 minutes). With prolonged infusions (>6-8 hours), deep tissue compartments approach saturation, and CSHT rises moderately to ~30-40 minutes.
• Fentanyl: Highly lipophilic with a large steady-state volume of distribution ($V_{d,\text{ss}} \approx 4\text{ L/kg}$) and modest clearance ($CL \approx 10-15\text{ mL/kg/min}$). Following a single bolus, awakening occurs within 10-15 minutes via redistribution into muscle and fat. However, during an infusion, deep peripheral reservoirs fill completely. Upon stopping an infusion that has lasted >2 hours, the concentration gradient reverses: drug diffuses back from saturated tissues into plasma, counteracting metabolic elimination. The CSHT rises exponentially, reaching 200 to 300 minutes after a 4- to 6-hour infusion.
• Sufentanil vs Alfentanil Crossover: For infusions lasting less than 7-8 hours, sufentanil exhibits a shorter CSHT than alfentanil because its higher clearance and greater lipid solubility allow more effective peripheral buffering. Only during ultra-prolonged infusions (>8 hours) does sufentanil's accumulation in deep fat reverse this advantage, at which point alfentanil's smaller $V_{d,\text{ss}}$ results in a lower CSHT.

---

6. Target-Controlled Infusion (TCI) and Effect-Site Equilibration

Target-Controlled Infusion (TCI) utilizes microprocessor-driven syringe pumps programmed with multi-compartmental pharmacokinetic and pharmacodynamic models. By continuously calculating compartmental transfers and systemic elimination, the pump administers a variable-rate infusion (the BET scheme: Bolus, Elimination, Transfer) to maintain a user-selected target concentration.

Effect-Site Targeting and the Rate Constant $k_{e0}$

The clinical effect of an intravenous anaesthetic is determined not by its concentration in plasma ($C_p$), but by its concentration at its receptor site in the central nervous system: the effect-site concentration ($C_e$). Because the blood-brain barrier and tissue diffusion introduce a physical delay, changes in $C_e$ lag behind changes in $C_p$. This temporal lag between drug concentration and clinical effect is termed hysteresis.

To model this lag, an apparent effect-site compartment ($V_e$) with negligible volume is coupled to the central compartment. Transfer is defined by the rate constant $k_{e0}$: $\frac{dC_e}{dt} = k_{e0} \times (C_p - C_e)$

• The rate constant $k_{e0}$ represents the rate of elimination from the effect-site compartment, governing the equilibration half-life ($t_{1/2,k_{e0}} = \frac{0.693}{k_{e0}}$).
• The time to peak effect ($t_{\text{peak}}$) following a rapid bolus is inversely related to $k_{e0}$: $t_{\text{peak}} = \frac{\ln(k_{e0}/\alpha)}{k_{e0} - \alpha}$
• Drugs with a large $k_{e0}$ (e.g., remifentanil $k_{e0} \approx 0.595\text{ min}^{-1}$, alfentanil $k_{e0} \approx 0.77\text{ min}^{-1}$) equilibrate rapidly with the brain ($t_{\text{peak}} \approx 1-1.5\text{ min}$), whereas drugs with a small $k_{e0}$ (e.g., midazolam $k_{e0} \approx 0.05-0.1\text{ min}^{-1}$) demonstrate marked hysteresis ($t_{\text{peak}} \approx 3-5\text{ min}$).

Propofol Models: Marsh vs Schnider

Remifentanil: The Minto Model

The Minto model is the universal standard for remifentanil TCI. It incorporates age, sex, weight, and height to compute Lean Body Mass (LBM via the James formula). Crucially, the Minto model adjusts for the progressive decline in central volume ($V_1$) and systemic clearance that occurs with aging:

• $V_1$ decreases from about 5.5 L in a 20-year-old to about 4.3 L in an 80-year-old (for a lean body mass of 55 kg).
• Clearance decreases from about 2.9 L/min to about 1.9 L/min over the same age span.
• The rate constant $k_{e0}$ declines with age: $k_{e0} = 0.595 - 0.007 \times (\text{age} - 40)$.

Clinical Trap with LBM in Morbid Obesity: The James formula for LBM relies on height and weight. In severely obese women (BMI above about $36\text{ kg/m}^2$) and men (BMI above about $43\text{ kg/m}^2$), the formula paradoxically calculates a declining LBM as weight increases, causing the TCI pump to deliver inappropriately small doses. In morbidly obese patients, TCI models should be programmed using adjusted body weight or newer allometric models (such as the Eleveld model) to avoid intraoperative awareness.